Selected research
Industry Growth & Trends
Global Endocrine Therapy Drugs (ETDs) Industry Growth and Trends Forecast to 2032
Market perspective
The global Endocrine Therapy Drugs (ETDs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Endocrine Therapy Drugs (ETDs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Endocrine Therapy Drugs (ETDs) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Endocrine Therapy Drugs (ETDs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Endocrine Therapy Drugs (ETDs) include Sanofi, Pfizer, Bayer, AstraZeneca, Tonghua Dongbao Pharmaceutical, Novo Nordisk, MSD, Huadong Medicine and Generex Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Endocrine Therapy Drugs (ETDs) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Endocrine Therapy Drugs (ETDs) market size, estimates, and forecasts are presented in terms of sales volume (Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Endocrine Therapy Drugs (ETDs) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Endocrine Therapy Drugs (ETDs).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Endocrine Therapy Drugs (ETDs) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Endocrine Therapy Drugs (ETDs) Market by Company
Sanofi
Pfizer
Bayer
AstraZeneca
Tonghua Dongbao Pharmaceutical
Novo Nordisk
MSD
Huadong Medicine
Generex Biotechnology
Endocrine Therapy Drugs (ETDs) Segment by Type
Antidiabetic Drugs
Anti-osteoporosis Drugs
Contraceptive
Other
Endocrine Therapy Drugs (ETDs) Segment by Application
Diabetes Treatment
Osteoporosis Treatment
Contraception
Other
Endocrine Therapy Drugs (ETDs) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endocrine Therapy Drugs (ETDs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endocrine Therapy Drugs (ETDs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endocrine Therapy Drugs (ETDs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Endocrine Therapy Drugs (ETDs) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Endocrine Therapy Drugs (ETDs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antidiabetic Drugs
- Anti-osteoporosis Drugs
- Contraceptive
- Other
Applications
- Diabetes Treatment
- Osteoporosis Treatment
- Contraception
- Other
Companies covered
- Sanofi
- Pfizer
- Bayer
- AstraZeneca
- Tonghua Dongbao Pharmaceutical
- Novo Nordisk
- MSD
- Huadong Medicine
- Generex Biotechnology
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Endocrine Therapy Drugs (ETDs) Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Endocrine Therapy Drugs (ETDs) Sales Estimates and Forecasts (2021-2032)
- 1.3 Endocrine Therapy Drugs (ETDs) Market by Type
- 1.3.1 Antidiabetic Drugs
- 1.3.2 Anti-osteoporosis Drugs
- 1.3.3 Contraceptive
- 1.3.4 Other
- 1.4 Global Endocrine Therapy Drugs (ETDs) Market Size by Type
- 1.4.1 Global Endocrine Therapy Drugs (ETDs) Market Size Overview by Type (2021-2032)
- 1.4.2 Global Endocrine Therapy Drugs (ETDs) Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Endocrine Therapy Drugs (ETDs) Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Endocrine Therapy Drugs (ETDs) Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Endocrine Therapy Drugs (ETDs) Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Endocrine Therapy Drugs (ETDs) Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Endocrine Therapy Drugs (ETDs) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Endocrine Therapy Drugs (ETDs) Industry Trends
- 2.2 Endocrine Therapy Drugs (ETDs) Industry Drivers
- 2.3 Endocrine Therapy Drugs (ETDs) Industry Opportunities and Challenges
- 2.4 Endocrine Therapy Drugs (ETDs) Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Endocrine Therapy Drugs (ETDs) Revenue (2021-2026)
- 3.2 Global Top Players by Endocrine Therapy Drugs (ETDs) Sales (2021-2026)
- 3.3 Global Top Players by Endocrine Therapy Drugs (ETDs) Price (2021-2026)
- 3.4 Global Endocrine Therapy Drugs (ETDs) Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Endocrine Therapy Drugs (ETDs) Major Company Production Sites & Headquarters
- 3.6 Global Endocrine Therapy Drugs (ETDs) Company, Product Type & Application
- 3.7 Global Endocrine Therapy Drugs (ETDs) Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Endocrine Therapy Drugs (ETDs) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Endocrine Therapy Drugs (ETDs) Players Market Share by Revenue in 2025
- 3.8.3 2025 Endocrine Therapy Drugs (ETDs) Tier 1, Tier 2, and Tier 3
4 Endocrine Therapy Drugs (ETDs) Regional Status and Outlook
- 4.1 Global Endocrine Therapy Drugs (ETDs) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Endocrine Therapy Drugs (ETDs) Historic Market Size by Region
- 4.2.1 Global Endocrine Therapy Drugs (ETDs) Sales in Volume by Region (2021-2026)
- 4.2.2 Global Endocrine Therapy Drugs (ETDs) Sales in Value by Region (2021-2026)
- 4.2.3 Global Endocrine Therapy Drugs (ETDs) Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Endocrine Therapy Drugs (ETDs) Forecasted Market Size by Region
- 4.3.1 Global Endocrine Therapy Drugs (ETDs) Sales in Volume by Region (2027-2032)
- 4.3.2 Global Endocrine Therapy Drugs (ETDs) Sales in Value by Region (2027-2032)
- 4.3.3 Global Endocrine Therapy Drugs (ETDs) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Endocrine Therapy Drugs (ETDs) by Application
- 5.1 Endocrine Therapy Drugs (ETDs) Market by Application
- 5.1.1 Diabetes Treatment
- 5.1.2 Osteoporosis Treatment
- 5.1.3 Contraception
- 5.1.4 Other
- 5.2 Global Endocrine Therapy Drugs (ETDs) Market Size by Application
- 5.2.1 Global Endocrine Therapy Drugs (ETDs) Market Size Overview by Application (2021-2032)
- 5.2.2 Global Endocrine Therapy Drugs (ETDs) Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Endocrine Therapy Drugs (ETDs) Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Endocrine Therapy Drugs (ETDs) Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Endocrine Therapy Drugs (ETDs) Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Endocrine Therapy Drugs (ETDs) Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Endocrine Therapy Drugs (ETDs) Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Sanofi Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Pfizer
- 6.2.1 Pfizer Company Information
- 6.2.2 Pfizer Business Overview
- 6.2.3 Pfizer Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Pfizer Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.2.5 Pfizer Recent Developments
- 6.3 Bayer
- 6.3.1 Bayer Company Information
- 6.3.2 Bayer Business Overview
- 6.3.3 Bayer Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Bayer Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.3.5 Bayer Recent Developments
- 6.4 AstraZeneca
- 6.4.1 AstraZeneca Company Information
- 6.4.2 AstraZeneca Business Overview
- 6.4.3 AstraZeneca Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 AstraZeneca Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.4.5 AstraZeneca Recent Developments
- 6.5 Tonghua Dongbao Pharmaceutical
- 6.5.1 Tonghua Dongbao Pharmaceutical Company Information
- 6.5.2 Tonghua Dongbao Pharmaceutical Business Overview
- 6.5.3 Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
- 6.6 Novo Nordisk
- 6.6.1 Novo Nordisk Company Information
- 6.6.2 Novo Nordisk Business Overview
- 6.6.3 Novo Nordisk Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Novo Nordisk Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.6.5 Novo Nordisk Recent Developments
- 6.7 MSD
- 6.7.1 MSD Company Information
- 6.7.2 MSD Business Overview
- 6.7.3 MSD Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 MSD Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.7.5 MSD Recent Developments
- 6.8 Huadong Medicine
- 6.8.1 Huadong Medicine Company Information
- 6.8.2 Huadong Medicine Business Overview
- 6.8.3 Huadong Medicine Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Huadong Medicine Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.8.5 Huadong Medicine Recent Developments
- 6.9 Generex Biotechnology
- 6.9.1 Generex Biotechnology Company Information
- 6.9.2 Generex Biotechnology Business Overview
- 6.9.3 Generex Biotechnology Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Generex Biotechnology Endocrine Therapy Drugs (ETDs) Product Portfolio
- 6.9.5 Generex Biotechnology Recent Developments
7 North America by Country
- 7.1 North America Endocrine Therapy Drugs (ETDs) Sales by Country
- 7.1.1 North America Endocrine Therapy Drugs (ETDs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2026)
- 7.1.3 North America Endocrine Therapy Drugs (ETDs) Sales Forecast by Country (2027-2032)
- 7.2 North America Endocrine Therapy Drugs (ETDs) Market Size by Country
- 7.2.1 North America Endocrine Therapy Drugs (ETDs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Endocrine Therapy Drugs (ETDs) Market Size by Country (2021-2026)
- 7.2.3 North America Endocrine Therapy Drugs (ETDs) Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Endocrine Therapy Drugs (ETDs) Sales by Country
- 8.1.1 Europe Endocrine Therapy Drugs (ETDs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2026)
- 8.1.3 Europe Endocrine Therapy Drugs (ETDs) Sales Forecast by Country (2027-2032)
- 8.2 Europe Endocrine Therapy Drugs (ETDs) Market Size by Country
- 8.2.1 Europe Endocrine Therapy Drugs (ETDs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Endocrine Therapy Drugs (ETDs) Market Size by Country (2021-2026)
- 8.2.3 Europe Endocrine Therapy Drugs (ETDs) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales by Country
- 9.1.1 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Endocrine Therapy Drugs (ETDs) Market Size by Country
- 9.2.1 Asia-Pacific Endocrine Therapy Drugs (ETDs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Endocrine Therapy Drugs (ETDs) Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Endocrine Therapy Drugs (ETDs) Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Endocrine Therapy Drugs (ETDs) Sales by Country
- 10.1.1 South America Endocrine Therapy Drugs (ETDs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2026)
- 10.1.3 South America Endocrine Therapy Drugs (ETDs) Sales Forecast by Country (2027-2032)
- 10.2 South America Endocrine Therapy Drugs (ETDs) Market Size by Country
- 10.2.1 South America Endocrine Therapy Drugs (ETDs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Endocrine Therapy Drugs (ETDs) Market Size by Country (2021-2026)
- 10.2.3 South America Endocrine Therapy Drugs (ETDs) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Endocrine Therapy Drugs (ETDs) Sales by Country
- 11.1.1 Middle East and Africa Endocrine Therapy Drugs (ETDs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Endocrine Therapy Drugs (ETDs) Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Endocrine Therapy Drugs (ETDs) Market Size by Country
- 11.2.1 Middle East and Africa Endocrine Therapy Drugs (ETDs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Endocrine Therapy Drugs (ETDs) Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Endocrine Therapy Drugs (ETDs) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Endocrine Therapy Drugs (ETDs) Value Chain Analysis
- 12.1.1 Endocrine Therapy Drugs (ETDs) Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Endocrine Therapy Drugs (ETDs) Production Mode & Process
- 12.2 Endocrine Therapy Drugs (ETDs) Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Endocrine Therapy Drugs (ETDs) Distributors
- 12.2.3 Endocrine Therapy Drugs (ETDs) Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst